Hepatic encephalopathy primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Aditya Ganti (talk | contribs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Usage of [[lactulose]] is helpful in prevention of HE in patients with [[cirrhosis]] and acute [[variceal bleeding]]. Lactulose may be effective to prevent of recurrence of hepatic encephalopathy in patients with [[cirrhosis]]. | |||
==Primary Prevention== | ==Primary Prevention== | ||
*Usage of [[lactulose]] is helpful in prevention of hepatic encephalopathy in patients with [[cirrhosis]] and acute [[Upper gastrointestinal bleeding|upper gastrointestinal bleeding.]]<ref name="pmid27310548">{{cite journal| author=Aires FT, Ramos PT, Bernardo WM| title=Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding. | journal=Rev Assoc Med Bras (1992) | year= 2016 | volume= 62 | issue= 3 | pages= 243-7 | pmid=27310548 | doi=10.1590/1806-9282.62.03.243 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27310548 }} </ref><ref name="pmid21129028">{{cite journal| author=Sharma P, Agrawal A, Sharma BC, Sarin SK| title=Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. | journal=J Gastroenterol Hepatol | year= 2011 | volume= 26 | issue= 6 | pages= 996-1003 | pmid=21129028 | doi=10.1111/j.1440-1746.2010.06596.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21129028 }} </ref> | *Usage of [[lactulose]] is helpful in [[prevention]] of hepatic encephalopathy in patients with [[cirrhosis]] and acute [[Upper gastrointestinal bleeding|upper gastrointestinal bleeding.]]<ref name="pmid27310548">{{cite journal| author=Aires FT, Ramos PT, Bernardo WM| title=Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding. | journal=Rev Assoc Med Bras (1992) | year= 2016 | volume= 62 | issue= 3 | pages= 243-7 | pmid=27310548 | doi=10.1590/1806-9282.62.03.243 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27310548 }} </ref><ref name="pmid21129028">{{cite journal| author=Sharma P, Agrawal A, Sharma BC, Sarin SK| title=Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. | journal=J Gastroenterol Hepatol | year= 2011 | volume= 26 | issue= 6 | pages= 996-1003 | pmid=21129028 | doi=10.1111/j.1440-1746.2010.06596.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21129028 }} </ref> | ||
*[[Lactulose]] may be effective to prevent of recurrence of hepatic encephalopathy in patients with cirrhosis.<ref name="pmid19501587">{{cite journal| author=Sharma BC, Sharma P, Agrawal A, Sarin SK| title=Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. | journal=Gastroenterology | year= 2009 | volume= 137 | issue= 3 | pages= 885-91, 891.e1 | pmid=19501587 | doi=10.1053/j.gastro.2009.05.056 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19501587 }} </ref> | *[[Lactulose]] may be effective to [[Prevention|prevent]] of recurrence of hepatic encephalopathy in patients with [[cirrhosis]].<ref name="pmid19501587">{{cite journal| author=Sharma BC, Sharma P, Agrawal A, Sarin SK| title=Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. | journal=Gastroenterology | year= 2009 | volume= 137 | issue= 3 | pages= 885-91, 891.e1 | pmid=19501587 | doi=10.1053/j.gastro.2009.05.056 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19501587 }} </ref> | ||
*Usage of [[lactitol]] or [[rifaximin]] is not effective in the prophylaxis of hepatic encephalopathy during the first month after a [[Transjugular intrahepatic portosystemic shunt|transjugular-intrahepatic-portosystemic-shunt (TIPS)]].<ref name="pmid15826716">{{cite journal| author=Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM et al.| title=Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. | journal=J Hepatol | year= 2005 | volume= 42 | issue= 5 | pages= 674-9 | pmid=15826716 | doi=10.1016/j.jhep.2004.12.028 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15826716 }} </ref> | *Usage of [[lactitol]] or [[rifaximin]] is not effective in the [[prophylaxis]] of hepatic encephalopathy during the first month after a [[Transjugular intrahepatic portosystemic shunt|transjugular-intrahepatic-portosystemic-shunt (TIPS)]].<ref name="pmid15826716">{{cite journal| author=Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM et al.| title=Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. | journal=J Hepatol | year= 2005 | volume= 42 | issue= 5 | pages= 674-9 | pmid=15826716 | doi=10.1016/j.jhep.2004.12.028 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15826716 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 05:35, 6 July 2020
|
Hepatic encephalopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatic encephalopathy primary prevention On the Web |
|
American Roentgen Ray Society Images of Hepatic encephalopathy primary prevention |
|
Risk calculators and risk factors for Hepatic encephalopathy primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
Usage of lactulose is helpful in prevention of HE in patients with cirrhosis and acute variceal bleeding. Lactulose may be effective to prevent of recurrence of hepatic encephalopathy in patients with cirrhosis.
Primary Prevention
- Usage of lactulose is helpful in prevention of hepatic encephalopathy in patients with cirrhosis and acute upper gastrointestinal bleeding.[1][2]
- Lactulose may be effective to prevent of recurrence of hepatic encephalopathy in patients with cirrhosis.[3]
- Usage of lactitol or rifaximin is not effective in the prophylaxis of hepatic encephalopathy during the first month after a transjugular-intrahepatic-portosystemic-shunt (TIPS).[4]
References
- ↑ Aires FT, Ramos PT, Bernardo WM (2016). "Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding". Rev Assoc Med Bras (1992). 62 (3): 243–7. doi:10.1590/1806-9282.62.03.243. PMID 27310548.
- ↑ Sharma P, Agrawal A, Sharma BC, Sarin SK (2011). "Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose". J Gastroenterol Hepatol. 26 (6): 996–1003. doi:10.1111/j.1440-1746.2010.06596.x. PMID 21129028.
- ↑ Sharma BC, Sharma P, Agrawal A, Sarin SK (2009). "Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo". Gastroenterology. 137 (3): 885–91, 891.e1. doi:10.1053/j.gastro.2009.05.056. PMID 19501587.
- ↑ Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM; et al. (2005). "Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study". J Hepatol. 42 (5): 674–9. doi:10.1016/j.jhep.2004.12.028. PMID 15826716.